Cipro I.V. (injection)
Generic name:ciprofloxacin (injection) [ SIP-roe-FLOX-a-sin ]
Drug class:Quinolones
What is Cipro I.V.?
Cipro I.V. is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. This medicine is used to treat different types of bacterial infections. This medicine is also used to treat people who have been exposed to anthrax or certain types of plague.
Fluoroquinolone antibiotics can cause serious or disabling side effects that may not be reversible. Cipro I.V. should be used only for infections that cannot be treated with a safer antibiotic.
Cipro I.V. may also be used for purposes not listed in this medication guide.
Warnings
Cipro I.V. can cause serious side effects, including tendon problems, nerve damage, serious mood or behavior changes, or low blood sugar.
Stop using Cipro I.V. and call your doctor at once if you have symptoms such as:headache, hunger, irritability, numbness, tingling, burning pain, confusion, agitation, paranoia, problems with memory or concentration, thoughts of suicide, or sudden pain or movement problems in any of your joints.
In rare cases, Cipro I.V. may cause damage to your aorta, which could lead to dangerous bleeding or death. Get emergency medical help if you have severe and constant pain in your chest, stomach, or back.
Before taking this medicine
You should not use Cipro I.V. if you are allergic to it, or if:
you are also taking tizanidine; or
you are allergic to other fluoroquinolones (gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and others).
Cipro I.V. may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the Achilles' tendon of the heel. This can happen during treatment or up to several months after you stop using this medicine. Tendon problems may be more likely in certain people (children and older adults, or people who use steroid medicine or have had an organ transplant).
Tell your doctor if you have ever had:
tendon problems, bone problems, arth...
